CHA2DS2-VASc Score Calculator

CHADS2 was the original 2001 Framingham-derived rule for stroke risk in nonvalvular atrial fibrillation and gave 1 point each for congestive heart failure, hypertension, age 75 or older, and diabetes, plus 2 points for prior stroke or TIA (maximum 6). The 2010 ESC refinement by Lip and colleagues added three modifiers that CHADS2 had missed: age 65 to 74 (1 point), vascular disease such as prior MI, peripheral artery disease, or aortic plaque (1 point), and sex category female (1 point), and also bumped age 75 or older from 1 to 2 points. The result is a 9-point scale that better separates truly low-risk patients (CHA2DS2-VASc 0) from low-but-not-zero risk patients, which matters because the threshold to start an oral anticoagulant is low.

The 2023 ACC/AHA/HRS atrial fibrillation guideline recommends oral anticoagulation when CHA2DS2-VASc is at or above 2 in men or at or above 3 in women. A direct oral anticoagulant (DOAC) such as apixaban, rivaroxaban, dabigatran, or edoxaban is preferred over warfarin in most patients, unless the patient has moderate-to-severe mitral stenosis or a mechanical heart valve, in which case warfarin remains the standard. For a score of 1 in a male patient, anticoagulation is reasonable (class IIa); for a score of 0, no antithrombotic therapy is recommended.

The original 2010 derivation showed that female sex was a risk modifier rather than an independent risk factor: in women with no other criteria, the absolute annual stroke rate is close to that of men with a score of 0, well under 1 percent. The 2023 ACC/AHA/HRS guideline, like the 2020 ESC update, therefore treats a score of 1 driven only by sex (a 60-year-old healthy woman, for example) as not warranting anticoagulation, because the bleeding risk on a DOAC would outweigh the small absolute stroke reduction. Once a second risk factor is present (score of 2 from sex plus age 65 to 74, hypertension, or any other criterion), the absolute risk rises sharply and anticoagulation is recommended.

For nonvalvular atrial fibrillation, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first-line in the 2023 ACC/AHA/HRS guideline because the ARISTOTLE, ROCKET-AF, RE-LY, and ENGAGE-AF trials showed equal or lower stroke prevention with significantly less intracranial hemorrhage compared to warfarin, and they need no routine INR monitoring. Apixaban has the lowest major bleeding rate in head-to-head observational data and is often preferred when bleeding risk is elevated. Warfarin still wins in three situations: moderate-to-severe mitral stenosis, a mechanical heart valve, or end-stage renal disease (creatinine clearance under 15 to 25 mL/min, depending on the DOAC), where DOAC dosing is poorly studied or contraindicated. Cost, drug interactions (especially with strong CYP3A4 or P-gp inducers), and reversal-agent access (idarucizumab for dabigatran, andexanet alfa for factor-Xa inhibitors) round out the decision.

HAS-BLED (hypertension, abnormal renal or liver function, prior stroke, prior bleeding, labile INR, elderly over 65, drugs or alcohol) estimates 1-year risk of major bleeding on anticoagulation. A score of 3 or more flags high bleeding risk but is not, on its own, a reason to withhold anticoagulation: the absolute stroke reduction from a DOAC in a patient with a CHA2DS2-VASc of 4 or higher almost always exceeds the absolute bleeding excess, even at HAS-BLED 3 or 4. The clinical use of HAS-BLED is to identify modifiable bleeding risks (uncontrolled hypertension, NSAID or excess alcohol use, labile INR on warfarin) and to set follow-up frequency, not to deny therapy. Many guidelines now favor ORBIT or ATRIA over HAS-BLED because they predict bleeding slightly better, but HAS-BLED remains the most widely used bedside score.